London/New York – Individualised medicines are getting ever closer. At the end of August, the US Food and Drug Administration, FDA, added information to the label of BristolMyers-Squibb’s Warfarin about how different genotypes may affect drug response to the blood thinner. FDA officials claimed this as huge step for personalised medicine becoming reality. The additional label information will help physicans to prescribe an individual effective dose and to separate responders from non-responders to the drug. For safe use of Warfarin, this might be essential as it can be metabolised in different ways. Genetic variations in the vkorc1 and cyp2C9 genes particularly increase the risk of bleeding and are said to cause 35% of Warfarin dose variation. Tests for the gene variations are offered by a range of commercial labs and could cost up to US$450. A decision from the FDA on whether Warfarin standard therapy requires genetic testing is expected by the end of the year.